Here are seven highlights:
1. Wayne Gersoff, MD, of Denver-based Advanced Orthopedics & Sports Medicine Specialists, performed the procedure on the 100th patient.
2. The NUsurface Meniscus Implant is designed to treat persistent knee pain stemming from deteriorating meniscus tissue.
3. Composed of medical grade polymer, the implant does not fixate to bone or soft tissues.
4. Active Implants President and CEO Ted Davis noted they hope to bring the implant to the U.S. market in the next two to three years, pending FDA clearance.
5. If cleared by the FDA, the NUsurface Meniscus Implant would be the first artificial meniscus on the market.
6. Surgeons have used the implant in Europe since 2008 and Israel since 2011.
7. Active Implants is sponsoring two trials, the VENUS and SUN trials. The VENUS trial is comparing the NUsurface Meniscus Implant to non-surgical standard of care. The SUN trial is testing the safety and effectiveness of the NUsurface Meniscus Implant.
More articles on devices:
Orthofix’s spine fixation sales jump 17.1% in Q2 2017 — 7 highlights
Medical device space leads healthcare M&A activity — 5 insights
K2M, Smith & Nephew & more: 9 device company mergers, acquisitions and agreements
